Board of Directors
Ian Bund, Director
Ian is Plymouth’s founding partner and has been active in venture capital investing since 1969. He brings extensive financial, operational and technological expertise to Plymouth Growth Partners.
Ian formed the first institutional VC in Michigan and has led or co-led 14 funds. He has been involved in building over 350 companies, executing over 40 IPOs, and serving on the Board of more than 20 businesses. Successful exits include numerous strategic sales, such as Ventana Medical Systems, Lifescan, Birtcher, Stratacom, and Neogen.
Ian received an MBA from Harvard University and a Bachelor of Economics from the University of Sydney. He is an Australian Chartered Accountant.
Chester Czaplicka, Director
Ann Arbor, Traverse City and metro Detroit area businessman Chet Czaplicka is a graduate of Wayne State University and the Harper Hospital School of Perfusion Technology. He is a registered nurse in both Michigan and Indiana, where he pursued a Master of Science degree in administration from the University of Notre Dame.
Chet currently serves as CEO of Comprehensive Care Services, one of the nation’s leaders in perfusion and autotranfusion services. Comprehensive Care Services is certified by the Joint Commission and provides superior perfusion and autotransfusion services. CCS Perioperative Blood Management Technologists (PBMT) are certified by the International Board of Blood Management. Chet is well known in Michigan as a successful entrepreneur. He is also co-owner of Grizzly Peak Brewing Company, Vinology wine bar, and The Blue Tractor in Ann Arbor, and North Peak Brewing Company in Traverse City.
Chet brings with him 25 years of hands on experience ranging from clinical perfusion and employee training to strategic planning and budgeting in a variety of professional settings.
Patricia Fanelli, Director
Patty Fanelli is the Senior Vice President and co-owner of Comprehensive Care Services. Patty is a Board Certified Clinical Perfusionist and has been working in Cardiac Surgery for over 30 years. She has a strong background in Joint Commission guidelines, CAP, CLIA and Federal regulations. She developed policies and procedures, education competencies, regulatory guidelines and training manuals currently used today in the field of Regenerative Medicine.
She was involved in the development of the “Medtronic StemPrep Kit” for BMAC use currently owned by Arteriocyte and has been a national speaker for Biologics since 2006 training hundreds of perfusionists and physicians in the world of Regenerative Medicine.
She also has strategic relationships with all National vendors, perfusion organizations and many Clinical Advisory Boards and trial sites allowing for the future growth of 3T Medical. Patty has her degree in Medical Technology and her postgraduate degree in Perfusion Technology.
Mark Horne, Board Observer
Mark is CEO & Managing Partner of Plymouth Ventures, a leading growth stage venture capital firm in Ann Arbor, Michigan with approximately $150 million under management. Plymouth invests in Great Lakes-based companies that have scalable technology, high growth and strong management teams and well-defined catalysts for growth.
Mark serves on the board of the Michigan Venture Capital Association, along with several Plymouth portfolio companies – Solulink, Image Integration Systems, Lynx Network Group, Relume Technologies, XanEdu Publishing and FutureNet.
Mark began his career with Price Waterhouse in Toronto and worked for 20 years as the chief financial officer of several privately-held growth stage businesses, ranging in size from $10 to $150 million. Mark is a former NJ licensed CPA. He holds an M.B.A. from Widener University and a B.B.A in business administration from Cedarville University.
Jack J. Kelley, Chief Executive Officer and Director
Dr. Jack Kelley is Chief Executive Officer and Board Member of 3T Medical Systems. Dr. Kelley has over 19 years of broad leadership experience in medical device and pharmaceutical drug delivery. Dr. Kelley has experience across a number of growth businesses and sectors key to healthcare commercialization and innovation, including, small and large cap medical device and pharmaceutical drug delivery corporations, venture capital, investment banking, and life science research.
Dr. Kelley has worked at Medtronic, JP Morgan and Becton Dickinson. Prior to 3T Medical Systems, he served as a Vice President of Unilife, an innovative drug delivery company with a proprietary prefillable syringe with retractable needle technology. Prior to Unilife, he served as the Worldwide Director, Strategic Marketing and Business Development at BD Pharmaceutical Systems, a leading supplier of conventional prefilled syringes. Dr. Kelley also served as Worldwide Director, Research and Development for BD Medical Surgical Systems, a leading supplier of acute care consumables. Prior to BD, Dr. Kelley was Manager, Ventures and Business Development for Medtronic Diabetes, a market and technology leader in insulin drug delivery, where he was responsible for the general medication infusion pump business development activities with pharmaceutical and biotechnology companies.
Prior to his industrial career, Dr. Kelley held a dual faculty appointment as a Research Assistant Professor at Dartmouth College in the Departments of Chemistry and Computer Science. Dr. Kelley has published patents and multiple peer reviewed journal articles on the biophysical characterization of proteins and DNA in solution. He holds a Doctorate in Biophysical Chemistry from Dartmouth College, an MBA from the University of Michigan, and a Bachelor’s degree in Chemistry from Marquette University.